LOG IN
SIGN UP
MARKET
XNCR
XNCR
Xencor
NASDAQ
30.86
+0.75
+2.49%
Closed 19:19 12/02 EST
OPEN
29.81
PREV CLOSE
30.11
HIGH
30.99
LOW
29.81
VOLUME
228.88K
TURNOVER
--
52 WEEK HIGH
42.30
52 WEEK LOW
19.36
MARKET CAP
1.85B
P/E (TTM)
66.19
1D
5D
1M
3M
1Y
5Y
Xencor's Return On Capital Employed Overview
Benzinga · 3d ago
Xencor (XNCR) Upgraded to Buy: Here's What You Should Know
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks · 11/25 17:00
Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif., November 10, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will par...
Business Wire · 11/10 21:01
Can Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Xencor (XNCR) points to a 74.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
Zacks · 11/10 14:55
Xencor Presents Early Clinical Data From Combination Study Of Vudalimab And New Data From Multiple Preclinical-Stage XmAb Programs At The SITC Annual Meeting
Benzinga · 11/10 14:27
RBC Capital Maintains Outperform on Xencor, Lowers Price Target to $36
Benzinga · 11/08 12:15
--RBC Cuts Price Target on Xencor to $36 From $40, Maintains Outperform Rating, Speculative Risk Qualifier
--RBC Cuts Price Target on Xencor to $36 From $40, Maintains Outperform Rating, Speculative Risk Qualifier
MT Newswires · 11/08 08:35
BRIEF-Xencor Reports Q3 Loss Per Share Of $0.55
Reuters · 11/07 21:32
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company is advancing a portfolio of clinical-stage XmAb drug candidates from its protein engineering technology platforms. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design technologies and XmAb development candidates with properties. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Tidutamab, XmAb841, XmAb306, AMG 509, XmAb819, XmAb104, XmAb564 and Novartis XmAb.
Webull offers kinds of Xencor Inc stock information, including NASDAQ:XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.